> Proteins and Antibodies>Proteins and Enzymes>Human / Cynomolgus VEGF / VEGFA / VEGF165 Protein

Proteins and Enzymes

Human / Cynomolgus VEGF / VEGFA / VEGF164 Protein View larger

Human / Cynomolgus VEGF / VEGFA / VEGF165 Protein

11066-HNAH

Activity: Measured in a cell proliferation assay using human umbilical vein endothelial cells (HUVEC). The ED50 for this effect is typically 4-16 ng/mL.

More details

Please ask for quote for unit smaller than 1 mg

Molarity Calculation Cart®

HOW TO ORDER

$2,998.00

$2,998.00 per mg

Add to my wishlist

Data sheet

Molecular WeightThe recombinant human VEGF165 consists of 165 amino acids and predicts a molecular mass of 19.2 KDa. It migrates as an approximately 20 and 22 KDa band in SDS-PAGE under reducing conditions.
Storage ConditionSamples are stable for up to twelve months from date of receipt at -70℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
Purity95% as determined by SDS-PAGE

More info

Protein Construction: A DNA sequence encoding the human VEGF165 isoform (P15692-4) (Met1-Arg191) was expressed. Human and Cynomolgus VEGF165 sequences are identical.

Formulation: Lyophilized from sterile 100 mM Glycine, 10 mM NaCl, pH 7.0.1. Normally 5% - 8% trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization. Specific concentrations are included in the hardcopy of COA.2. Please contact us for any concerns or special requirements.Please refer to the specific buffer information in the hard copy of CoA.

Reconstitution: A hardcopy of COA with reconstitution instruction is sent along with the products. Please refer to it for detailed information.

VEGFA Background Information: Vascular endothelial growth factor (VEGF), also known as vascular permeability factor (VPF) and VEGF-A, is a potent mediator of both angiogenesis and vasculogenesis in the fetus and adult. It is a member of the platelet-derived growth factor (PDGF)/vascular endothelial growth factor (VEGF) family and often exists as a disulfide-linked homodimer. VEGF-A protein is a glycosylated mitogen that specifically acts on endothelial cells and has various effects, including mediating increased vascular permeability, inducing angiogenesis, vasculogenesis and endothelial cell growth, promoting cell migration, inhibiting apoptosis and tumor growth. VEGF-A protein is also a vasodilator that increases microvascular permeability, thus it was originally referred to as vascular permeability factor.

References:

  • Woolard J. et al. (2004) VEGF165b, an inhibitory vascular endothelial growth factor splice variant: mechanism of action, in vivo effect on angiogenesis and endogenous protein expression. Cancer Res. 64(21): 7822-7835.
  • Jia SF, et al. (2008) VEGF165 is necessary to the metastatic potential of Fas(-) osteosarcoma cells but will not rescue the Fas(+) cells. J Exp Ther Oncol. 7(2): 89-97.
  • Cimpean AM, et al. (2008) Vascular endothelial growth factor A (VEGF A) as individual prognostic factor in invasive breast carcinoma. Rom J Morphol Embryol. 49(3): 303-8.
  • Hamdollah Zadeh MA, et al. (2008) VEGF-mediated elevated intracellular calcium and angiogenesis in human microvascular endothelial cells in vitro are inhibited by dominant negative TRPC6. Microcirculation. 15(7): 605-14.
  • Eisenach PA, et al. (2010) MT1-MMP regulates VEGF-A expression through a complex with VEGFR-2 and Src. J Cell Sci. 123(Pt 23):4182-4193.
  • Claesson-Welsh L (2010) Gremlin: vexing VEGF receptor agonist. Blood. 116(18):3386-7.